

SUPPLEMENTARY FIGURES



Supplementary Figure 1. Validation of the cuproptosis-related immune signature in the GSE81540 dataset. (A) The Kaplan-Merier curves for the overall survival of risk groups in the validation set. (B) The predictive accuracy of signature for 1-,3- and 5-year OS in the validation set. (C) The distribution of TNBC patients according to risk score and survival status. (D) The different expressions of nine selected genes between high- and low-risk groups. (E) Univariate Cox and multivariate Cox (F) analysis of prognostic factors in TNBC patients.



Supplementary Figure 2. Validation of the cuproptosis-related immune signature and two genes in datasets. (A) The Kaplan-Merier curves for the overall survival of risk groups in the validation set GSE58812. (B) The predictive accuracy of signature for 1-,3- and 5year OS in GSE58812. (C, D) The distribution of TNBC patients according to risk score(C) and survival status (D). (E) Identification of seven significant cell clusters in TNBC scRNA-seq GSE188600. (F) Validation of THY1 and IDO1 expression in different cell clusters in TNBC scRNA-seq GSE188600.